Darbepoetin alfa, a new therapy for the management of anemia of chronic kidney disease.
- 1 September 2002
- journal article
- research article
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 22 (9), 141S-149S
- https://doi.org/10.1592/phco.22.14.141s.33397
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Anemia: An early complication of chronic renal insufficiencyAmerican Journal of Kidney Diseases, 2001
- Defining a renal anemia management periodAmerican Journal of Kidney Diseases, 2000
- Optimization of pre-ESRD care: The key to improved dialysis outcomesKidney International, 2000
- Chairman's workshop report. How should anaemia be managed in pre-dialysis patients?Nephrology Dialysis Transplantation, 1999
- Serum creatinine levels in the US population: Third National Health and Nutrition Examination SurveyAmerican Journal of Kidney Diseases, 1998
- Reversal of Anemia by Erythropoietin Therapy Retards the Progression of Chronic Renal Failure, Especially in Nondiabetic PatientsNephron, 1997
- Quality of life in predialytic uremic patientsQuality of Life Research, 1996
- Cardiac function and hematocrit levelAmerican Journal of Kidney Diseases, 1995
- The quality of life of hemodialysis recipients treated with recombinant human erythropoietin. Cooperative Multicenter EPO Clinical Trial GroupJAMA, 1990
- The anemia of chronic renal failure: Pathophysiology and the effects of recombinant erythropoietinKidney International, 1989